Your browser doesn't support javascript.
loading
Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture.
Zheng, Hou-Feng; Forgetta, Vincenzo; Hsu, Yi-Hsiang; Estrada, Karol; Rosello-Diez, Alberto; Leo, Paul J; Dahia, Chitra L; Park-Min, Kyung Hyun; Tobias, Jonathan H; Kooperberg, Charles; Kleinman, Aaron; Styrkarsdottir, Unnur; Liu, Ching-Ti; Uggla, Charlotta; Evans, Daniel S; Nielson, Carrie M; Walter, Klaudia; Pettersson-Kymmer, Ulrika; McCarthy, Shane; Eriksson, Joel; Kwan, Tony; Jhamai, Mila; Trajanoska, Katerina; Memari, Yasin; Min, Josine; Huang, Jie; Danecek, Petr; Wilmot, Beth; Li, Rui; Chou, Wen-Chi; Mokry, Lauren E; Moayyeri, Alireza; Claussnitzer, Melina; Cheng, Chia-Ho; Cheung, Warren; Medina-Gómez, Carolina; Ge, Bing; Chen, Shu-Huang; Choi, Kwangbom; Oei, Ling; Fraser, James; Kraaij, Robert; Hibbs, Matthew A; Gregson, Celia L; Paquette, Denis; Hofman, Albert; Wibom, Carl; Tranah, Gregory J; Marshall, Mhairi; Gardiner, Brooke B.
Afiliación
  • Zheng HF; Departments of Medicine, Human Genetics, Epidemiology and Biostatistics, McGill University, Montréal H3A 1A2, Canada.
  • Forgetta V; Department of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal H3T 1E2, Canada.
  • Hsu YH; Departments of Medicine, Human Genetics, Epidemiology and Biostatistics, McGill University, Montréal H3A 1A2, Canada.
  • Estrada K; Department of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal H3T 1E2, Canada.
  • Rosello-Diez A; Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts 02131, USA.
  • Leo PJ; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Dahia CL; Broad Institute of MIT and Harvard, Boston, Massachusetts 02115, USA.
  • Park-Min KH; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Tobias JH; Broad Institute of MIT and Harvard, Boston, Massachusetts 02115, USA.
  • Kooperberg C; Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015GE, The Netherlands.
  • Kleinman A; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
  • Styrkarsdottir U; Developmental Biology Program, Sloan Kettering Institute, New York, New York 10065, USA.
  • Liu CT; The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane 4102, Australia.
  • Uggla C; Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York 10065, USA.
  • Evans DS; Tissue Engineering, Regeneration and Repair Program, Hospital for Special Surgery, New York 10021, USA.
  • Nielson CM; Rheumatology Divison, Hospital for Special Surgery New York, New York 10021, USA.
  • Walter K; School of Clinical Science, University of Bristol, Bristol BS10 5NB, UK.
  • Pettersson-Kymmer U; MRC Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN, UK.
  • McCarthy S; Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
  • Eriksson J; Department of Research, 23andMe, Mountain View, California 94041, USA.
  • Kwan T; Department of Population Genomics, deCODE Genetics, Reykjavik IS-101, Iceland.
  • Jhamai M; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA.
  • Trajanoska K; Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-413 45, Sweden.
  • Memari Y; California Pacific Medical Center Research Institute, San Francisco, California 94158, USA.
  • Min J; Department of Public Health and Preventive Medicine, Oregon Health &Science University, Portland, Oregon 97239, USA.
  • Huang J; Bone &Mineral Unit, Oregon Health &Science University, Portland, Oregon 97239, USA.
  • Danecek P; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
  • Wilmot B; Departments of Pharmacology and Clinical Neurosciences, Umeå University, Umeå S-901 87, Sweden.
  • Li R; Department of Public Health and Clinical Medicine, Umeå University, Umeå SE-901 87, Sweden.
  • Chou WC; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
  • Mokry LE; Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-413 45, Sweden.
  • Moayyeri A; Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-413 45, Sweden.
  • Claussnitzer M; McGill University and Genome Quebec Innovation Centre, Montréal H3A 0G1, Canada.
  • Cheng CH; Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015GE, The Netherlands.
  • Cheung W; Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015GE, The Netherlands.
  • Medina-Gómez C; Department of Epidemiology, Erasmus Medical Center, Rotterdam 3015GE, The Netherlands.
  • Ge B; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
  • Chen SH; MRC Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN, UK.
  • Choi K; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
  • Oei L; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
  • Fraser J; Oregon Clinical and Translational Research Institute, Oregon Health &Science University, Portland, Oregon 97239, USA.
  • Kraaij R; Department of Medical and Clinical Informatics, Oregon Health &Science University, Portland, Oregon 97239, USA.
  • Hibbs MA; Departments of Medicine, Human Genetics, Epidemiology and Biostatistics, McGill University, Montréal H3A 1A2, Canada.
  • Gregson CL; Department of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal H3T 1E2, Canada.
  • Paquette D; Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts 02131, USA.
  • Hofman A; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Wibom C; Department of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montréal H3T 1E2, Canada.
  • Tranah GJ; Farr Institute of Health Informatics Research, University College London, London NW1 2DA, UK.
  • Marshall M; Department of Twin Research and Genetic Epidemiology, King's College London, London SE1 7EH, UK.
  • Gardiner BB; Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts 02131, USA.
Nature ; 526(7571): 112-7, 2015 Oct 01.
Article en En | MEDLINE | ID: mdl-26367794
The extent to which low-frequency (minor allele frequency (MAF) between 1-5%) and rare (MAF ≤ 1%) variants contribute to complex traits and disease in the general population is mainly unknown. Bone mineral density (BMD) is highly heritable, a major predictor of osteoporotic fractures, and has been previously associated with common genetic variants, as well as rare, population-specific, coding variants. Here we identify novel non-coding genetic variants with large effects on BMD (ntotal = 53,236) and fracture (ntotal = 508,253) in individuals of European ancestry from the general population. Associations for BMD were derived from whole-genome sequencing (n = 2,882 from UK10K (ref. 10); a population-based genome sequencing consortium), whole-exome sequencing (n = 3,549), deep imputation of genotyped samples using a combined UK10K/1000 Genomes reference panel (n = 26,534), and de novo replication genotyping (n = 20,271). We identified a low-frequency non-coding variant near a novel locus, EN1, with an effect size fourfold larger than the mean of previously reported common variants for lumbar spine BMD (rs11692564(T), MAF = 1.6%, replication effect size = +0.20 s.d., Pmeta = 2 × 10(-14)), which was also associated with a decreased risk of fracture (odds ratio = 0.85; P = 2 × 10(-11); ncases = 98,742 and ncontrols = 409,511). Using an En1(cre/flox) mouse model, we observed that conditional loss of En1 results in low bone mass, probably as a consequence of high bone turnover. We also identified a novel low-frequency non-coding variant with large effects on BMD near WNT16 (rs148771817(T), MAF = 1.2%, replication effect size = +0.41 s.d., Pmeta = 1 × 10(-11)). In general, there was an excess of association signals arising from deleterious coding and conserved non-coding variants. These findings provide evidence that low-frequency non-coding variants have large effects on BMD and fracture, thereby providing rationale for whole-genome sequencing and improved imputation reference panels to study the genetic architecture of complex traits and disease in the general population.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Densidad Ósea / Genoma Humano / Proteínas de Homeodominio / Fracturas Óseas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Nature Año: 2015 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Densidad Ósea / Genoma Humano / Proteínas de Homeodominio / Fracturas Óseas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Nature Año: 2015 Tipo del documento: Article País de afiliación: Canadá
...